Streetbeat News

Equity Actions

PCSA

Processa Pharmaceuticals' stock is trading lower following the announcement of a $7 million public offering pricing.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:46 pm

NVVE

Nuvve Corporation's stock is trading lower following the announcement of a public offering involving 2.3 million shares of common stock and various series of warrants. This move typically dilutes existing shareholders and can put downward pressure on the stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:36 pm

MSFT

TSLA

Elon Musk's AI company, xAI, is reportedly in talks to raise $6 billion, potentially valuing it at $20 billion. Morgan Stanley is assisting with the fundraising. xAI, with team members from OpenAI, Google Research, Microsoft Research, and DeepMind, is expanding AI efforts with projects like Grok. The funding could face scrutiny due to geopolitical concerns. Musk's wealth has decreased by $30.9 billion in 2024, but he remains the richest person with a $198 billion net worth. He also plans to increase his Tesla stake to 25% for AI integration.

Portfolio Pulse from Chris Katje

January 26, 2024 | 3:30 pm

HAL

Halliburton's (NYSE:HAL) short interest has increased to 21.19 million shares, or 2.68% of float, which is below its peer group average of 7.88%. The rise in short interest suggests that market sentiment may be bearish, but it does not necessarily predict a near-term price drop. It takes traders approximately 3.26 days to cover their short positions based on current trading volume.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:30 pm

TKLF

Yoshitsu Co., Ltd. shares have dropped following the announcement of a $4 million registered direct offering and private placement.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 3:30 pm

SHW

Sherwin-Williams (NYSE:SHW) has been analyzed by 6 financial analysts, showing a shift towards a more neutral stance over the last quarter. The average 12-month price target is now $325.83, up from $296.00, with individual targets ranging from $300.00 to $378.00. Analysts from Wells Fargo, UBS, Baird, Argus Research, and Goldman Sachs have all raised their price targets. Sherwin-Williams is a leading architectural paint provider in the U.S. with strong financial performance indicators such as a 1.15% revenue growth rate, a net margin of 12.45%, ROE of 20.55%, and ROA of 3.3%, but carries a high debt-to-equity ratio of 3.14.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:01 pm

IDYA

IDEAYA Biosciences (NASDAQ:IDYA) has received mixed analyst ratings over the last quarter, with 3 bullish and 5 somewhat bullish ratings. The average 12-month price target for IDYA is $44.5, with a high of $53.00 and a low of $36.00, representing a 16.49% increase from the previous average of $38.20. Analysts from firms including Goldman Sachs, RBC Capital, JP Morgan, Wedbush, and Guggenheim have updated their ratings and price targets. IDEAYA Biosciences is an oncology-focused precision medicine company with a negative revenue trend of -72.94% over 3 months and a high net margin of -341.38%. The company has a strong ROE of -5.44% and ROA of -5.17%, with no debt (debt-to-equity ratio of 0.0).

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:00 pm

URI

United Rentals (NYSE:URI) has received mixed analyst ratings over the last quarter, with 6 analysts offering varied opinions. The average 12-month price target for URI is $576.83, with a high estimate of $710.00 and a low of $485.00, marking an 8.94% increase from the previous target. Recent actions by analysts include rating changes and price target adjustments, reflecting their views on the company's performance and market conditions. United Rentals, the world's largest equipment rental company, has shown strong financials with a market cap above industry average, a revenue growth rate of 13.11%, a net margin of 18.21%, an ROE of 8.55%, an ROA of 2.64%, and a debt-to-equity ratio of 1.56.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:00 pm

ASB

Associated Banc (NYSE:ASB) has been analyzed by 4 analysts in the last three months, with all maintaining an indifferent rating. The average 12-month price target for ASB is $20.38, up from the previous $19.50. Analysts from RBC Capital, Keefe, Bruyette & Woods, and Piper Sandler have raised their price targets. Associated Banc operates in banking and nonbanking services, with the majority of revenue from Corporate and Commercial Specialty and Community, Consumer, and Business segments. The company's market cap is below industry averages, and it has seen a -4.44% decline in revenue growth, a net margin of 25.06%, an ROE of 2.03%, an ROA of 0.19%, and a high debt-to-equity ratio of 1.08.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:00 pm

PCSA

Processa Pharmaceuticals has announced the pricing of a $7 million public offering. This capital raise could impact the company's financial flexibility and potentially fund further development of its product pipeline.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:46 pm